Advertisement

European Journal of Clinical Pharmacology

, Volume 75, Issue 12, pp 1723–1730 | Cite as

National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus

  • Jisu Kim
  • Susin Park
  • Hyunsoo Kim
  • Nam Kyung JeEmail author
Pharmacoepidemiology and Prescription
  • 211 Downloads

Abstract

Background

The American Diabetes Association guidelines recommend metformin monotherapy for type 2 diabetes mellitus as an initial agent due to its effectiveness and safety. If the target glycosylated haemoglobin level is not attained within 3 months, add-on therapy is recommended. This study aimed to investigate the prescribing trends of add-on therapy to metformin focusing on factors affecting the selection of second agents using real-world data.

Methods

Patients who were undergoing metformin monotherapy for at least 3 months and switched to metformin-based combination therapy were selected. The oral antidiabetic drugs used as add-on therapy were classified into 4 classes: dipeptidyl peptidase-4 inhibitors (DPP4I), sodium glucose cotransporter-2 inhibitors (SGLT2I), sulphonylureas (SU), and thiazolidinediones (TZD). The drug regimen was also classified as older and newer agents. Chi-square test and logistic regression analysis were performed to estimate the influencing factors.

Results

In 2014–2016, the use of DPP4I and SGLT2I increased, whereas the use of SU and TZD decreased. Our results show that the prescription pattern was influenced by the type and location of the institution, specialty of physicians, some comorbidities, and patient characteristics such as age and sex. Newer agents were more commonly used in younger patients. SGLT2I were more preferred in women than in men. Patients with dyslipidaemia showed increased odds of utilising newer agents.

Conclusion

DPP4I were the most commonly utilised agents in metformin-based combination therapy and SGLT2I use is expected to increase more due to their cardioprotective effects. Proper selection of add-on therapy, based on drug-specific effects and patient factors, is necessary.

Keywords

Diabetes mellitus Antidiabetic drug Add-on therapy 

Notes

Acknowledgements

The Health Insurance Review and Assessment Service (HIRA) National Patient Sample from 2014 to 2016 (HIRA-NPS-2014-0061, HIRA-NPS-2015-0059, HIRA-NPS-2016-0058) was used for this study; however, the results do not concern the Ministry of Health and Welfare or HIRA.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

228_2019_2751_MOESM1_ESM.docx (24 kb)
ESM 1 (DOCX 24 kb)

References

  1. 1.
    Alam U, Asghar O, Azmi S, Malik RA (2014) General aspects of diabetes mellitus. Handb Clin Neurol 126:211–222.  https://doi.org/10.1016/b978-0-444-53480-4.00015-1 CrossRefPubMedGoogle Scholar
  2. 2.
    Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE, Makaroff LE (2017) IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 128:40–50.  https://doi.org/10.1016/j.diabres.2017.03.024 CrossRefGoogle Scholar
  3. 3.
    Ha KH, Kim DJ (2016) Current status of managing diabetes mellitus in Korea. Korean J Intern Med 31(5):845–850.  https://doi.org/10.3904/kjim.2016.253 CrossRefGoogle Scholar
  4. 4.
    (2018) 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care 41 (Suppl 1): S73-s85 DOI  https://doi.org/10.2337/dc18-S008
  5. 5.
    Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, Woo MH, Kim JY, Kim NH, Kim JT, Kim CH, Kim HJ, Jeong IK, Hong EK, Cho JH, Mok JO, Yoon KH (2011) 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 35(5):431–436.  https://doi.org/10.4093/dmj.2011.35.5.431 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Moon MK, Hur KY, Ko SH, Park SO, Lee BW, Kim JH, Rhee SY, Kim HJ, Choi KM, Kim NH (2017) Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. Korean J Intern Med 32(6):974–983.  https://doi.org/10.3904/kjim.2017.354 CrossRefGoogle Scholar
  7. 7.
    Ko SH, Han K, Lee YH, Noh J, Park CY, Kim DJ, Jung CH, Lee KU, Ko KS (2018) Past and current status of adult type 2 diabetes mellitus management in Korea: a National Health Insurance Service database analysis. Diabetes Metab J 42(2):93–100.  https://doi.org/10.4093/dmj.2018.42.2.93 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chu WM, Ho HE, Huang KH, Tsan YT, Liou YS, Wang YH, Lee MC, Li YC (2017) The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: an 8-year population-based study. Medicine 96(43):e8257.  https://doi.org/10.1097/md.0000000000008257 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Cohen FJ, Neslusan CA, Conklin JE, Song X (2003) Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care 26(6):1847–1851CrossRefGoogle Scholar
  10. 10.
    Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM (2009) Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 18(10):973–976.  https://doi.org/10.1002/pds.1802 CrossRefPubMedGoogle Scholar
  11. 11.
    Boyc KS, Yurgin N, Lage MJ (2007) Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians. Adv Ther 24(4):803–813CrossRefGoogle Scholar
  12. 12.
    Baviera M, Monesi L, Marzona I, Avanzini F, Monesi G, Nobili A, Tettamanti M, Riva E, Cortesi L, Bortolotti A, Fortino I, Merlino L, Fontana G, Roncaglioni MC (2011) Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy’s Lombardy Region: a large population-based study. Diabetes Res Clin Pract 93(1):123–130.  https://doi.org/10.1016/j.diabres.2011.05.004 CrossRefPubMedGoogle Scholar
  13. 13.
    Sharma M, Nazareth I, Petersen I (2016) Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open 6(1):e010210.  https://doi.org/10.1136/bmjopen-2015-010210 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ko SH, Kim DJ, Park JH, Park CY, Jung CH, Kwon HS, Park JY, Song KH, Han K, Lee KU, Ko KS (2016) Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: nationwide population-based cohort study. Medicine 95(27):e4018.  https://doi.org/10.1097/md.0000000000004018 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lee Y-K, Ha Y-C, Yoon B-H, Koo K-H (2014) National trends of hip arthroscopy in Korea. J Korean Med Sci 29(2):277–280.  https://doi.org/10.3346/jkms.2014.29.2.277 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Mishriky BM, Cummings DM, Tanenberg RJ (2015) The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 109(2):378–388.  https://doi.org/10.1016/j.diabres.2015.05.025 CrossRefPubMedGoogle Scholar
  17. 17.
    Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF (2016) Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. Jama 316(3):313–324.  https://doi.org/10.1001/jama.2016.9400 CrossRefPubMedGoogle Scholar
  18. 18.
    Zhou JB, Bai L, Wang Y, Yang JK (2016) The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial. Int J Clin Pract 70(2):132–141.  https://doi.org/10.1111/ijcp.12761 CrossRefPubMedGoogle Scholar
  19. 19.
    Foroutan N, Muratov S, Levine M (2016) Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis. Clin Invest Med 39(2):E48–E62CrossRefGoogle Scholar
  20. 20.
    Reed JW (2016) Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag 12:393–405.  https://doi.org/10.2147/vhrm.S111991 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S (2016) Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 164(11):740–751.  https://doi.org/10.7326/m15-2650 CrossRefPubMedGoogle Scholar
  22. 22.
    Ribola FA, Cancado FB, Schoueri JH, De Toni VF, Medeiros VH, Feder D (2017) Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci 21(1):199–211PubMedGoogle Scholar
  23. 23.
    Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34(9):2015–2022.  https://doi.org/10.2337/dc11-0606 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941–950.  https://doi.org/10.1016/s0140-6736(13)60683-2 CrossRefGoogle Scholar
  25. 25.
    Abdelhafiz AH, Sinclair AJ (2013) Management of type 2 diabetes in older people. Diabetes Ther 4(1):13–26.  https://doi.org/10.1007/s13300-013-0020-4 CrossRefGoogle Scholar
  26. 26.
    Huang ES (2016) Management of diabetes mellitus in older people with comorbidities. BMJ 353:i2200.  https://doi.org/10.1136/bmj.i2200 CrossRefPubMedGoogle Scholar
  27. 27.
    Park E-J, Kwon J-W, Lee E-K, Jung Y-H, Park S (2015) Out-of-pocket medication expenditure burden of elderly Koreans with chronic conditions. Int J Gerontol 9(3):166–171.  https://doi.org/10.1016/j.ijge.2014.06.005 CrossRefGoogle Scholar
  28. 28.
    Cha SA, Park YM, Yun JS, Lim TS, Song KH, Yoo KD, Ahn YB, Ko SH (2017) A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis 16(1):58.  https://doi.org/10.1186/s12944-017-0443-4 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S (2012) A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol 696(1–3):194–202.  https://doi.org/10.1016/j.ejphar.2012.09.024 CrossRefPubMedGoogle Scholar
  30. 30.
    Masuda D, Kobayashi T, Sairyou M, Hanada H, Ohama T, Koseki M, Nishida M, Maeda N, Kihara S, Minami T, Yanagi K, Sakata Y, Yamashita S (2018) Effects of a dipeptidyl peptidase 4 inhibitor sitagliptin on glycemic control and lipoprotein metabolism in patients with type 2 diabetes mellitus (GLORIA trial). J Atheroscler Thromb 25(6):512–520.  https://doi.org/10.5551/jat.41343 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Yale JF (2005) Oral antihyperglycemic agents and renal disease: new agents, new concepts. J Am Soc Nephrol 16 Suppl 1: S7–10Google Scholar
  32. 32.
    Krepinsky J, Ingram AJ, Clase CM (2000) Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 35(3):500–505CrossRefGoogle Scholar
  33. 33.
    Khan R, Foster GR, Chowdhury TA (2012) Managing diabetes in patients with chronic liver disease. Postgrad Med 124(4):130–137.  https://doi.org/10.3810/pgm.2012.07.2574 CrossRefPubMedGoogle Scholar
  34. 34.
    Scheen AJ (2014) Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet 53(9):773–785.  https://doi.org/10.1007/s40262-014-0157-y CrossRefPubMedGoogle Scholar
  35. 35.
    Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, Qureshi MF, Md F, Pathan MF, Jawad F, Bhattarai J, Tandon N, Somasundaram N, Katulanda P, Sahay R, Dhungel S, Bajaj S, Chowdhury S, Ghosh S, Madhu SV, Ahmed T, Bulughapitiya U (2015) lace of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: a consensus statement. Indian J Endocrinol Metab 19(5):577–596.  https://doi.org/10.4103/2230-8210.163171 CrossRefGoogle Scholar
  36. 36.
    (2018) 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care 41 (Suppl 1): S86-s104 DOI  https://doi.org/10.2337/dc18-S009

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.College of PharmacyPusan National UniversityBusanRepublic of Korea

Personalised recommendations